D. Schlichting

473 total citations
27 papers, 371 citations indexed

About

D. Schlichting is a scholar working on Rheumatology, Genetics and Oncology. According to data from OpenAlex, D. Schlichting has authored 27 papers receiving a total of 371 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Rheumatology, 8 papers in Genetics and 8 papers in Oncology. Recurrent topics in D. Schlichting's work include Rheumatoid Arthritis Research and Therapies (23 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Systemic Lupus Erythematosus Research (8 papers). D. Schlichting is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (23 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Systemic Lupus Erythematosus Research (8 papers). D. Schlichting collaborates with scholars based in United States, United Kingdom and Canada. D. Schlichting's co-authors include C. Gaich, William L. Macias, Kim Papp, Alan Menter, Maitreyi Raman, X. Zhang, Jonathan Janes, Damon Disch, Scott D. Beattie and M. C. Genovese and has published in prestigious journals such as Annals of the Rheumatic Diseases, British Journal of Dermatology and Lara D. Veeken.

In The Last Decade

D. Schlichting

27 papers receiving 361 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D. Schlichting United States	9	205	158	121	92	89	27	371
Sarah Witt United States	5	422 2.1×	96 0.6×	135 1.1×	213 2.3×	40 0.4×	6	560
Sebastian Meerwein United States	8	524 2.6×	158 1.0×	193 1.6×	299 3.3×	35 0.4×	23	675
Lucian Ionescu United Kingdom	7	308 1.5×	299 1.9×	29 0.2×	158 1.7×	188 2.1×	9	599
Pilar Bravo Spain	11	66 0.3×	228 1.4×	63 0.5×	60 0.7×	61 0.7×	14	371
F Navaux France	6	202 1.0×	133 0.8×	65 0.5×	59 0.6×	8 0.1×	9	357
Caylib Durand Canada	9	41 0.2×	158 1.0×	43 0.4×	55 0.6×	20 0.2×	15	328
Catherine Lawson United Kingdom	5	277 1.4×	357 2.3×	36 0.3×	132 1.4×	33 0.4×	7	464
Nigel Patton New Zealand	7	66 0.3×	96 0.6×	83 0.7×	102 1.1×	22 0.2×	12	276
E. Keystone Canada	8	259 1.3×	86 0.5×	33 0.3×	108 1.2×	14 0.2×	26	357
Anna Tasidou Greece	9	67 0.3×	43 0.3×	106 0.9×	187 2.0×	12 0.1×	13	375

Countries citing papers authored by D. Schlichting

Since Specialization

Citations

This map shows the geographic impact of D. Schlichting's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Schlichting with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Schlichting more than expected).

Fields of papers citing papers by D. Schlichting

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Schlichting. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Schlichting. The network helps show where D. Schlichting may publish in the future.

Co-authorship network of co-authors of D. Schlichting

This figure shows the co-authorship network connecting the top 25 collaborators of D. Schlichting. A scholar is included among the top collaborators of D. Schlichting based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Schlichting. D. Schlichting is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gordon, Stuart C., Sheri Trudeau, Arie Regev, et al.. (2021). Baricitinib and primary biliary cholangitis. Journal of Translational Autoimmunity. 4. 100107–100107. 18 indexed citations

Boesen, Mikael, Scott D. Beattie, D. Schlichting, & Olga Kubassova. (2021). Novel quantitative digital image analysis methodology for assessment of inflammatory changes in MRI data in a post-hoc analysis of data acquired from a phase IIb study of baricitinib in patients with active rheumatoid arthritis. European Journal of Radiology. 143. 109877–109877. 1 indexed citations

Genovese, M. C., Josef S Smolen, Tsutomu Takeuchi, et al.. (2020). FRI0123 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 8.4 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS. Annals of the Rheumatic Diseases. 79. 642–643. 9 indexed citations

Peterfy, Charles, Julie C. DiCarlo, Paul Emery, et al.. (2019). MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. The Journal of Rheumatology. 46(8). 887–895. 7 indexed citations

Taylor, Peter C., R Fleischmann, Elizabeth L. Perkins, et al.. (2017). Rapid and Sustained Pain Improvement in Rheumatoid Arthritis Patients Treated with Baricitinib Compared to Adalimumab or Placebo. Oxford University Research Archive (ORA) (University of Oxford). 69. 1 indexed citations

Emery, Paul, Peter C. Taylor, M. Weinblatt, et al.. (2017). Microarray Pathway Analysis Comparing Baricitinib and Adalimumab in Moderate to Severe Rheumatoid Arthritis Patients, from a Phase 3 Study. Oxford University Research Archive (ORA) (University of Oxford). 69. 2 indexed citations

Genovese, Mark C., Désirée van der Heijde, Maxime Dougados, et al.. (2017). BARICITINIB INHIBITS RADIOGRAPHIC PROGRESSION OF STRUCTURAL JOINT DAMAGE AT 1 YEAR IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS). Internal Medicine Journal. 47. 32–32. 1 indexed citations

Taylor, Peter C., Baojin Zhu, C. Gaich, et al.. (2017). SAT0055 Baricitinib showed rapid and greater reduction in pain compared to adalimumab or placebo in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 76. 788–788. 3 indexed citations

Dougados, Maxime, D. van der Heijde, Maria Greenwald, et al.. (2016). Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to cDMARD Therapy: Results of the Phase 3 RA-BUILD Study. The Journal of Rheumatology. 43(6). 1188–1188. 2 indexed citations

10.

Schiff, Michael, Tsutomu Takeuchi, C. Gaich, et al.. (2016). THU0623 Patient-Reported Outcomes from A Phase 3 Study of Baricitinib in Patients with Early Rheumatoid Arthritis Who Had Received Limited or No Treatment with Disease-Modifying anti-Rheumatic Drugs. Annals of the Rheumatic Diseases. 75. 419–419. 5 indexed citations

11.

Taylor, Peter C., E C Keystone, D. van der Heijde, et al.. (2015). Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study. Data Archiving and Networked Services (DANS). 67. 8–8. 15 indexed citations

12.

Genovese, M. C., Joel M. Kremer, Omid Zamani, et al.. (2015). OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study. Annals of the Rheumatic Diseases. 74. 75–76. 20 indexed citations

13.

Dougados, Maxime, D. van der Heijde, Yu‐Chi Chen, et al.. (2015). LB0001 Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and An Inadequate Response to CDMARD Therapy: Results of the Phase 3 RA-Build Study. Annals of the Rheumatic Diseases. 74. 79–79. 24 indexed citations

14.

Taylor, Paul C.J., M. C. Genovese, E. Keystone, et al.. (2015). THU0175 Effects of Baricitinib on Multibiomarker Disease Activity Scores and Their Components in a Phase 2B Study in Moderate-to-Severe Rheumatoid Arthritis Patients. Annals of the Rheumatic Diseases. 74. 257–258. 1 indexed citations

15.

Taylor, Peter C., Mark C. Genovese, Edward Keystone, et al.. (2013). 24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS. Lara D. Veeken. 52. 44–45. 1 indexed citations

16.

Taylor, Paul C.J., et al.. (2013). OP0047 Baricitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Study. Annals of the Rheumatic Diseases. 72. A65–A66. 2 indexed citations

17.

Smolen, Josef S, D. Schlichting, K.L. Sterling, et al.. (2012). 12-and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. Arthritis & Rheumatism. 64. 5 indexed citations

18.

Genovese, M. C., Ed Keystone, P. W. J. Taylor, et al.. (2012). 24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.. Oxford University Research Archive (ORA) (University of Oxford). 64(10). 10 indexed citations

19.

Peterfy, Charles, Paul Emery, M. C. Genovese, et al.. (2012). Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.. Oxford University Research Archive (ORA) (University of Oxford). 8 indexed citations

20.

Keystone, Ed, Peter C. Taylor, Mark C. Genovese, et al.. (2012). LB0005 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional dmards in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 71. 152–153. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact